Judith Finegold, a biopharmaceutical analyst at Capital Group and former cardiologist, shares her insights on drug innovation and investment. She discusses the years of research behind blockbuster drugs like Ozempic, the evolving landscape of drug pricing, and the shift towards advanced therapies. Topics include the promise of genetic sequencing in drug discovery, the impact of GLP-1 drugs in treating obesity, and the transformative role of antibody drug conjugates in cancer care. Finegold emphasizes the necessity of understanding both science and business for successful investing in biopharma.